Physical compatibility of pentoxifylline and intravenous medications
- 24 November 2018
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 104 (3), 292-295
- https://doi.org/10.1136/archdischild-2018-315376
Abstract
Objective To investigate the physical and chemical compatibility of pentoxifylline (PTX) with a wide range of parenteral medications used in the neonatal intensive care setting. Design PTX and drug solutions were combined in glass phials and inspected visually for physical incompatibility. The chemical compatibility was evaluated on the basis of PTX concentrations. Results Precipitation, colour change or turbidity was not visible in any of the test mixtures, indicating no observed physical incompatibility or apparent risk of blockage in narrow-bore intravenous tubing. The PTX concentration was approximately 2.5% and 4.5% lower when combined with dopamine and amoxicillin, respectively. The PTX concentration ratios for all other combinations were in the range of 99%–102%. Conclusion In simulated Y-site conditions, physical compatibility testing of PTX and 30 parenteral medications revealed no evidence of precipitation. Based on PTX concentration tests, it could be prudent to avoid mixing PTX with dopamine or amoxicillin.Keywords
Funding Information
- Telethon Channel 7 Women’s and Infants’ Research Foundation
This publication has 4 references indexed in Scilit:
- Compatibility of intravenous pentoxifylline with other medications infused concurrently in preterm infants with late‐onset sepsisActa Paediatrica, 2018
- Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonatesJournal of Pharmaceutical and Biomedical Analysis, 2017
- Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonatesCochrane Database of Systematic Reviews, 2015
- Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injectionAmerican Journal of Health-System Pharmacy, 1995